Colgate-Palmolive (NYSE:CL) Upgraded by StockNews.com to “Buy” Rating

Colgate-Palmolive (NYSE:CL) was upgraded by research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report released on Monday.

Several other analysts have also recently issued reports on CL. Redburn Atlantic raised Colgate-Palmolive to a “hold” rating in a report on Thursday, August 1st. Morgan Stanley boosted their price target on Colgate-Palmolive from $103.00 to $111.00 and gave the company an “overweight” rating in a report on Monday, July 29th. Piper Sandler started coverage on Colgate-Palmolive in a research report on Tuesday, September 24th. They set an “overweight” rating and a $121.00 price target for the company. Wells Fargo & Company decreased their target price on Colgate-Palmolive from $100.00 to $92.00 and set an “underweight” rating on the stock in a research note on Monday, October 28th. Finally, Barclays upped their price target on Colgate-Palmolive from $91.00 to $96.00 and gave the stock an “equal weight” rating in a report on Monday, July 29th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $105.11.

Colgate-Palmolive Price Performance

NYSE CL traded up $0.42 on Monday, reaching $95.34. 6,048,626 shares of the company’s stock traded hands, compared to its average volume of 4,391,036. The stock has a 50-day simple moving average of $97.90 and a 200 day simple moving average of $98.58. Colgate-Palmolive has a 12 month low of $75.50 and a 12 month high of $109.30. The stock has a market cap of $77.89 billion, a PE ratio of 27.32, a P/E/G ratio of 3.39 and a beta of 0.42. The company has a debt-to-equity ratio of 9.46, a current ratio of 1.04 and a quick ratio of 0.68.

Insider Buying and Selling

In other news, CFO Stanley J. Sutula III sold 45,410 shares of the firm’s stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $94.11, for a total transaction of $4,273,535.10. Following the sale, the chief financial officer now owns 36,726 shares of the company’s stock, valued at $3,456,283.86. This trade represents a 55.29 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.37% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Colgate-Palmolive

Several institutional investors have recently bought and sold shares of CL. E Fund Management Hong Kong Co. Ltd. purchased a new position in shares of Colgate-Palmolive in the 2nd quarter worth about $25,000. Continuum Advisory LLC grew its holdings in shares of Colgate-Palmolive by 46.5% during the second quarter. Continuum Advisory LLC now owns 394 shares of the company’s stock valued at $38,000 after buying an additional 125 shares in the last quarter. Reston Wealth Management LLC purchased a new position in Colgate-Palmolive in the third quarter valued at about $42,000. Capital Performance Advisors LLP acquired a new stake in shares of Colgate-Palmolive in the third quarter worth about $53,000. Finally, Prospera Private Wealth LLC bought a new position in Colgate-Palmolive during the third quarter valued at about $64,000. 80.41% of the stock is owned by institutional investors and hedge funds.

Colgate-Palmolive Company Profile

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.